vs
ImmunityBio, Inc.（IBRX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是ImmunityBio, Inc.的1.3倍（$50.3M vs $38.3M），READING INTERNATIONAL INC净利率更高（-5.1% vs -161.8%，领先156.7%），ImmunityBio, Inc.同比增速更快（407.0% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $-71.3M）
ImmunityBio, Inc.是一家处于临床阶段的生物技术企业，专注开发针对多种癌症及传染性疾病的下一代免疫疗法与候选疫苗，核心研发方向涵盖细胞疗法、抗体药物及靶向疫苗平台，主要运营市场位于美国。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
IBRX vs RDI — 直观对比
营收规模更大
RDI
是对方的1.3倍
$38.3M
营收增速更快
IBRX
高出421.1%
-14.2%
净利率更高
RDI
高出156.7%
-161.8%
自由现金流更多
RDI
多$75.4M
$-71.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $50.3M |
| 净利润 | $-61.9M | $-2.6M |
| 毛利率 | 99.0% | — |
| 营业利润率 | -169.0% | -1.9% |
| 净利率 | -161.8% | -5.1% |
| 营收同比 | 407.0% | -14.2% |
| 净利润同比 | -4.7% | -14.5% |
| 每股收益（稀释后） | $-0.06 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBRXRDI
| Q4 25 | $38.3M | $50.3M | ||
| Q3 25 | $32.1M | $52.2M | ||
| Q2 25 | $26.4M | $60.4M | ||
| Q1 25 | $16.5M | $40.2M | ||
| Q4 24 | $7.6M | $58.6M | ||
| Q3 24 | $6.1M | $60.1M | ||
| Q2 24 | — | $46.8M | ||
| Q1 24 | — | $45.1M |
净利润IBRXRDI
| Q4 25 | $-61.9M | $-2.6M | ||
| Q3 25 | $-67.3M | $-4.2M | ||
| Q2 25 | $-92.6M | $-2.7M | ||
| Q1 25 | $-129.6M | $-4.8M | ||
| Q4 24 | $-59.2M | $-2.2M | ||
| Q3 24 | $-85.7M | $-7.0M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | — | $-13.2M |
毛利率IBRXRDI
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IBRXRDI
| Q4 25 | -169.0% | -1.9% | ||
| Q3 25 | -173.5% | -0.6% | ||
| Q2 25 | -269.8% | 4.8% | ||
| Q1 25 | -390.1% | -17.2% | ||
| Q4 24 | -919.0% | 2.6% | ||
| Q3 24 | -1314.3% | -0.6% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | — | -16.7% |
净利率IBRXRDI
| Q4 25 | -161.8% | -5.1% | ||
| Q3 25 | -209.8% | -8.0% | ||
| Q2 25 | -350.3% | -4.4% | ||
| Q1 25 | -784.9% | -11.8% | ||
| Q4 24 | -783.4% | -3.8% | ||
| Q3 24 | -1404.0% | -11.7% | ||
| Q2 24 | — | -27.4% | ||
| Q1 24 | — | -29.4% |
每股收益（稀释后）IBRXRDI
| Q4 25 | $-0.06 | $-0.11 | ||
| Q3 25 | $-0.07 | $-0.18 | ||
| Q2 25 | $-0.10 | $-0.12 | ||
| Q1 25 | $-0.15 | $-0.21 | ||
| Q4 24 | $-0.08 | $-0.11 | ||
| Q3 24 | $-0.14 | $-0.31 | ||
| Q2 24 | — | $-0.57 | ||
| Q1 24 | — | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $242.8M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $-500.5M | $-18.2M |
| 总资产 | $501.9M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IBRXRDI
| Q4 25 | $242.8M | $10.5M | ||
| Q3 25 | $257.8M | $8.1M | ||
| Q2 25 | $153.7M | $9.1M | ||
| Q1 25 | $61.6M | $5.9M | ||
| Q4 24 | $149.8M | $12.4M | ||
| Q3 24 | $130.4M | $10.1M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $7.5M |
总债务IBRXRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IBRXRDI
| Q4 25 | $-500.5M | $-18.2M | ||
| Q3 25 | $-524.3M | $-12.1M | ||
| Q2 25 | $-570.7M | $-7.7M | ||
| Q1 25 | $-591.4M | $-8.1M | ||
| Q4 24 | $-489.1M | $-4.4M | ||
| Q3 24 | $-745.1M | $1.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | — | $18.0M |
总资产IBRXRDI
| Q4 25 | $501.9M | $434.9M | ||
| Q3 25 | $519.0M | $435.2M | ||
| Q2 25 | $402.1M | $438.1M | ||
| Q1 25 | $303.8M | $441.0M | ||
| Q4 24 | $382.9M | $471.0M | ||
| Q3 24 | $364.6M | $495.7M | ||
| Q2 24 | — | $494.9M | ||
| Q1 24 | — | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.4M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $-71.3M | $4.1M |
| 自由现金流率自由现金流/营收 | -186.2% | 8.2% |
| 资本支出强度资本支出/营收 | 2.4% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-308.8M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流IBRXRDI
| Q4 25 | $-70.4M | $4.3M | ||
| Q3 25 | $-68.9M | $295.0K | ||
| Q2 25 | $-79.7M | $1.6M | ||
| Q1 25 | $-85.9M | $-7.7M | ||
| Q4 24 | $-85.1M | $8.0M | ||
| Q3 24 | $-98.8M | $1.3M | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | — | $-2.8M |
自由现金流IBRXRDI
| Q4 25 | $-71.3M | $4.1M | ||
| Q3 25 | $-69.6M | $-246.0K | ||
| Q2 25 | $-80.8M | $1.2M | ||
| Q1 25 | $-87.0M | $-8.0M | ||
| Q4 24 | $-87.3M | $7.0M | ||
| Q3 24 | $-101.6M | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-4.7M |
自由现金流率IBRXRDI
| Q4 25 | -186.2% | 8.2% | ||
| Q3 25 | -217.2% | -0.5% | ||
| Q2 25 | -305.9% | 1.9% | ||
| Q1 25 | -526.9% | -19.8% | ||
| Q4 24 | -1155.4% | 12.0% | ||
| Q3 24 | -1663.2% | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | — | -10.4% |
资本支出强度IBRXRDI
| Q4 25 | 2.4% | 0.3% | ||
| Q3 25 | 2.3% | 1.0% | ||
| Q2 25 | 4.1% | 0.6% | ||
| Q1 25 | 6.8% | 0.6% | ||
| Q4 24 | 28.0% | 1.7% | ||
| Q3 24 | 45.7% | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 4.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBRX
暂无分部数据
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
